Clinical Study

Nrg-Lu003- A Biomarker-Driven Protocol For Previously Treated Alk-Positive Non-Squamous Nsclc Patients: The Nci-Nrg Alk Master Protocol

Posted Date: Feb 5, 2020

  • Investigator: John Morris
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to assess whether ALK kinase domain mutations associated with drug resistance are prognostic for objective response to subsequent ALK inhibitor therapy and To evaluate objective responses of patients with specific genetic alterations treated with crizotinib.


Must Have Confirmed Stage Iv Alk-Positive Non- Squamous Nsclc, Age = 18, Progressive Disease, Ecog 0-2, Surgery Or Rt Within 2 Weeks, No Hx Of Other Malignancy Within 2 Years


Lung, Nsclc

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.